Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Portable 12V&24V Jump Starter with Lithium lron Phosphate
Contact UsJump Starter featuring advanced lithium iron phosphate technology.
-
Metal cloths
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
-
1500A Jump Starter with Air Compressor
Contact UsExperience ultimate convenience and reliability with our 1500A Jump Starter featuring a 150 PSI Air Compressor, ensuring you’re always prepared for any roadside emergency.
Reviews
There are no reviews yet.